What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and Others

Purpose of Review Inflammatory bowel disease (IBD), such as Crohn’s disease (CD) and ulcerative colitis (UC), is an unmet need as indicated by less than ideal remission rates with current treatments. Understanding the clinical development of approved IBD biological therapy, particularly dose selection, may help improve future biologic development.